<DOC>
	<DOCNO>NCT00078026</DOCNO>
	<brief_summary>Osteoporosis affect million postmenopausal woman USA . The current approved treatment drug prevent bone loss possibly result small gain bone mass . Another possible treatment consist drug increase bone formation . There currently two drug stimulate bone formation , sodium fluoride human parathyroid hormone ( hPTH ) . Neither two drug approve FDA . APOMINE show significant bone formation animal study . In study plan test whether APOMINE able stimulate new bone formation woman osteoporosis low bone mass .</brief_summary>
	<brief_title>An Investigation Into Short Term Effect APOMINE Patients With Osteoporosis Low Bone Mass</brief_title>
	<detailed_description>This study randomize , placebo-controlled , double-blind , parallel-group study investigate efficacy safety administer 3 dose level APOMINE 25 , 50 , 100 mg/day placebo day capsule postmenopausal woman low bone mass osteoporosis . Eligible patient must woman 45 75 year age , diagnose low bone mineral density osteoporosis , least 3 year post menopause . The primary endpoint study change bone formation marker ( bone alkaline phosphatase osteocalcin ) . The secondary endpoint study change bone formation marker ( bone alkaline phosphatase , osteocalcin , P-ICP ) bone resorption marker ( serum C-telopeptide , urinary N-telopeptide ) . Blood sample draw study visit determine bone marker well normal laboratory test . Bone mineral density measurement ( DEXA ) perform begin end study . Up 60 subject randomize cohort treatment treat 25 , 50 , 100 mg/day placebo ( 15 subject per group ) . All enrolled subject receive daily calcium Vitamin D supplement .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>A diagnosis osteoporosis low bone mass ( T score &lt; = 1 ) . Female , 45 75 year old ( inclusive ) . Postmenopausal ( cessation menses oophorectomy ) least 3 year . Bone mineral density : ( BMD ) spine hip &gt; 1 standard deviation mean young normal sex ( T score &lt; = 1 ) . Adequate liver function indicate total bilirubin , AST , ALT within institutional normal limit . Serum creatinine within institutional normal limit . Signed , write informed consent . Able comply study procedure followup examination . Ionized calcium 25hydroxyvitamin D3 must within institutional normal limit . PTH must within institutional normal limit . Known hypersensitivity study drug relate compound ( e.g. , bisphosphonates ) . Use drug treatment osteoporosis previous 6 month ( e.g. , bisphosphonates , hormonereplacement therapy [ HRT ] ) . Any chronic continue use drug know affect bone metabolism ( e.g. , diuretic , glucocorticoid , oral contraceptive ) . Gallstone diagnose within past 5 year history multiple gallstone . Previous significant gastrointestinal surgery ( except appendectomy ) gastrointestinal disease . Abnormal thyroid function ( thyroidstimulating hormone [ TSH ] assay , normal range 0.55.0 U/L ) . Secondary osteoporosis ( e.g. , steroidinduced ) and/or disorder affect calcium mineral metabolism . Use investigational agent within previous 30 day . Patients exist heart problem ( e.g. , congestive heart failure , unstable angina , conduction delay ) . Patients take calcium channel blocker , beta blocker , digitalis , antihypertensive agent . Any concurrent disease condition , judgment investigator , would make patient inappropriate entry study .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Apomine</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone Mass</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>